During the recent session, Mersana Therapeutics Inc (NASDAQ:MRSN)’s traded shares were 0.69 million, with the beta value of the company hitting 1.54. At the last check today, the stock’s price was $0.53, reflecting an intraday gain of 4.22% or $0.02. The 52-week high for the MRSN share is $6.28, that puts it down -1084.91 from that peak though still a striking 13.21% gain since the share price plummeted to a 52-week low of $0.46. The company’s market capitalization is $66.55M, and the average trade volume was 5.48 million shares over the past three months.
Mersana Therapeutics Inc (MRSN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. MRSN has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.19.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Mersana Therapeutics Inc (MRSN) registered a 4.22% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.22% in intraday trading to $0.53, hitting a weekly high. The stock’s 5-day price performance is 6.18%, and it has moved by -11.74% in 30 days. Based on these gigs, the overall price performance for the year is -90.71%.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 82.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $3 respectively. As a result, MRSN is trading at a discount of -466.04% off the target high and -466.04% off the low.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
In the rating firms’ projections, revenue will decrease -32.93% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.05M as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 6.12M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 9.24M and 2.29M respectively. In this case, analysts expect current quarter sales to shrink by -34.58% and then jump by 166.98% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 2.74%. While earnings are projected to return -25.99% in 2025, the next five years will return -13.09% per annum.
MRSN Dividends
Mersana Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
The next largest institutional holding, with 11.33 million shares, is of VR ADVISER, LLC’s that is approximately 9.2519% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.77 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mersana Therapeutics Inc (MRSN) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 3.47 shares. This amounts to just over 2.81 percent of the company’s overall shares, with a $1.84 million market value. The same data shows that the other fund manager holds slightly less at 3.11, or about 2.52% of the stock, which is worth about $1.65 million.
